Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
13 search results for:

Synthetic lethality 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-06-2017 | PARP inhibitors | Article

    Synthetic lethality and cancer

    The review explores the advances made and challenges of exploiting the genetic phenomenon of synthetic lethality to indentify new anticancer therapeutic targets. Nat Rev Gen 2017;18:613–623. doi:10.1038/nrg.2017.47

    Author:
    Nigel J O'Neill, Melanie L Bailey, Philip Hieter
  2. 22-06-2017 | PARP inhibitors | Article

    Targeting DNA repair and replication stress in the treatment of ovarian cancer

    This review examines the rationale behind and strategies for DNA repair inhibitors and cell cycle checkpoint inhibitors, as single agent therapy and in combination with DNA damaging agents in ovarian cancer. Murai J. Int J Clin Oncol  2017;22:619–628. doi:10.1007/s10147-017-1145-7

  3. 25-05-2017 | PARP inhibitors | Article

    PARP Inhibitors in prostate cancer

    Geethakumari PR, Schiewer MJ, Knudsen KE, Kelly WK. Curr Treat Options in Oncol 2017;18:37. doi10.1007/s11864-017-0480-2

  4. 05-07-2017 | PARP inhibitors | Article

    The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

    These DSBs would not be repaired in the absence of BRCA proteins, thus causing synthetic lethality.

    Author:
    Arnab Chaudhuri, Andre Nussenzweig
  5. 05-06-2018 | Castration-resistant prostate cancer | ASCO 2018 | Article

    Olaparib has clinical efficacy in men with metastatic castration-resistant prostate cancer

    In an accompanying commentary , Emmanuel Antonarakis (Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, USA) hypothesizes that combining androgen receptor-targeted therapy with PARP1-targeted therapy may result in a “a new type of synthetic lethality”.

    Published in:
    Lancet Oncol 2018; Advance online publication
  6. 13-10-2016 | PARP inhibitors | Article

    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: Current practice and future directions

    PARP inhibitor activity Synthetic lethality Genetically, synthetic lethality occurs when two genetic lesions, which are individually not lethal, become lethal when combined in a single organism (or cell).

    Author:
    G E Konecny, R S Kristeleit

  7. Introduction

    This synthetic lethality has rendered the PARP1 inhibitors particularly useful in tumors with BRCA1 or BRCA2 loss-of-function mutations.

  8. 13-12-2016 | Ovarian cancer | Article

    Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

    The mechanism of action of PARP inhibitors involves use of synthetic lethality to exploit the DNA repair functions of PARP.

    Author:
    Angela George, Stan Kaye, Susana Banerjee
  9. 13-12-2016 | PARP inhibitors | Article

    Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

    The mechanism of action of PARP inhibitors involves use of synthetic lethality to exploit the DNA repair functions of PARP.

    Author:
    Angela George, Stan Kaye, Susana Banerjee
  10. 15-12-2015 | Ovarian cancer | Article

    The development of PARP inhibitors in ovarian cancer: from bench to bedside

    This proposed mechanism of synthetic lethality of PARP inhibitors in BRCA -deficient cells is outlined in Figure 3.

    Author:
    Yvette Drew
  11. 08-11-2016 | PARP inhibitors | Article

    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

    Olaparib (Lynparza) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor that blocks base-excision repair by trapping PARP at sites of DNA damage, leading to synthetic lethality in tumour cells with deficiencies in homologous recombination repair, such as those with BRCA1/2 mutations ( BRCA m) (Evers et al , 2008; Rottenberg et al , 2008).

    Author:
    Jonathan A Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Bryan Bennett, David Parry, Stuart Spencer, Helen Mann, Ursula Matulonis
  12. 17-05-2016 | Triple-negative breast cancer | Article

    Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease

    Therefore, inhibition of PARP1 by RNA interference or with chemical inhibitors leads to severe, highly selective toxicity in  BRCA1  and  BRCA2 -defective cells 97 , so-called 'synthetic lethality' (Ref. 98).

    Author:
    Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Luca Gianni
  13. 15-12-2015 | Gynecologic cancers | Article

    UK BRCA mutation testing in patients with ovarian cancer

    There is also interest in identifying patients with somatic mutations in DNA repair genes such as  BRCA1  and  BRCA2 , as they may demonstrate similar synthetic lethality to PARP inhibitors as that shown with germline mutations.

    Author:
    Angela George
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.